C-Bridge Capital, a Shanghai-based private equity firm focused on China's healthcare sector, hopes to profit handsomely by bringing better drug know-how from developed markets to the underdeveloped Chinese pharmaceutical industry.
Headed by finance veteran Fu Wei, the US$700 million-under-management firm led a follow-on US$100 million round in Chinese pharmaceutical start-up Ascletis earlier this month. Ascletis has licensed and conducted clinical trail on a hepatitis C treatment drug developed by an American company, and is launching the drug in China during the first half of this year.
The sheer scale of the Chinese market makes the investment attractive, says Fu, a University of Chicago Booth School of Business graduate. With 40 million hepatitis C patients in China, compared to just four million in the U.S., he is confident that the drug will hit it big and bring ...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network
